Detalhe da pesquisa
1.
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.
J Infect Dis
; 228(7): 868-877, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141388
2.
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
Asian Pac J Allergy Immunol
; 2023 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37466962
3.
Bioequivalence Study of 100-mg Cilostazol Tablets in Healthy Thai Adult Volunteers.
Curr Ther Res Clin Exp
; 91: 11-16, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31372190
4.
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
BMC Health Serv Res
; 14: 151, 2014 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24708579
5.
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis.
Front Pharmacol
; 14: 1184552, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37288109
6.
Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
Front Immunol
; 14: 1302041, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38274835
7.
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Int J Infect Dis
; 129: 19-31, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36682680
8.
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.
Hum Vaccin Immunother
; 19(2): 2228670, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439770
9.
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Vaccine
; 41(40): 5834-5840, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37586956
10.
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
Emerg Microbes Infect
; 11(1): 2197-2206, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35997325
11.
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
Front Immunol
; 13: 1010835, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36268028
12.
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Hum Vaccin Immunother
; 18(6): 2091865, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35816053
13.
Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations.
Front Immunol
; 13: 1080791, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36733395
14.
Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study.
Vaccines (Basel)
; 10(9)2022 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36146575
15.
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers.
Vaccine X
; 10: 100153, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35282410
16.
Bioequivalence study of 50 mg sertraline tablets in healthy Thai volunteers.
J Med Assoc Thai
; 92(9): 1229-33, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19772184
17.
Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene.
PeerJ
; 7: e6501, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30828495
18.
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.
J Infect
; 85(4): 436-480, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728642